Avalo Therapeutics CFO Sullivan Christopher Ryan exercised Options for 10,185 shares at $8.04 per share on 2026-09-10 and sold 10,185 shares at $17.62. For investors, the transactions leave him with 50,085 shares after the exercise, 39,900 after the sale and 105,815 derivative securities.

Key Highlights

  • Sullivan Christopher Ryan held 50,085 shares after the option exercise.
  • The sale left Avalo Therapeutics’ CFO with 39,900 shares.
  • His derivative securities position stood at 105,815 after the exercise, representing about 8.8% of his prior holding.

Avalo Therapeutics, Inc. (NASDAQ: AVTX) CFO Sullivan Christopher Ryan exercised options for 10,185 shares at $8.04 per share on 10 September 2026.

CFO’s Share Transactions on September 10

Following that transaction, Sullivan owned 50,085 Avalo Therapeutics shares, with the exercise representing about 20.3% of his resulting shareholding. A separate transaction code S identified the sale of 10,185 shares at $17.62 per share. After the sale, his shareholding stood at 39,900 shares, and the transaction represented about 20.3% of his prior shareholding.

Derivative Securities Position Reaches 105,815

The option exercise also covered 10,185 derivative securities. Sullivan owned 105,815 derivative securities after that transaction, representing about 8.8% of his prior derivative securities holding.